Table 2 Main rheumatic diseases and concomitant medication at baseline
| Â | N (%) |
|---|---|
Rheumatic disease | Â |
Systemic lupus erythematous | 4243 (82.5) |
Rheumatoid arthritis | 402 (7.8) |
Primary Sjögren syndrome | 192 (3.7) |
Mixed connective tissue disease | 75 (1.5) |
Osteoarthritis | 66 (1.3) |
Systemic sclerosis | 43 (0.8) |
Inflammatory myopathies | 34 (0.7) |
Chikungunya | 18 (0.4) |
Other | 69 (1.3) |
Antimalarials | Â |
Hydroxychloroquine (HCQ) | 5035 (97.5) |
HCQ use time (years), mean (SD) | 7.2 (6.2) |
Chloroquine diphosphate (CD) | 131 (2.5) |
CD use time (years), mean (SD) | 10.6 (7.4) |
Concomitant medication related to RD | Â |
Glucocorticoids | 1895 (36.7) |
 < 10 mg/day | 1394 (73.6) |
 ≥ 10 mg/day | 462 (24.4) |
Ibuprofen | 35 (0.7) |
IV Methylprednisolone (pulse) | 30 (0.6) |
Cyclophosphamide (oral and pulse) | 73 (1.4) |
Synthetic conventional DMARDs | 2444 (47.3) |
Methotrexate | 631 (12.2) |
Sulfasalazine | 16 (0.3) |
Azathioprine | 983 (19.0) |
Leflunomide | 96 (1.9) |
Cyclosporine | 80 (1.5) |
Mycophenolate mofetil | 657 (12.7) |
Biological or target-specific DMARDs | 181 (3.5) |
TNF inhibitors | 17 (0.3) |
Belimumab | 52 (1.0) |
Rituximab | 81 (1.6) |
Abatacept | 17 (0.3) |
Tocilizumab | 7 (0.1) |
Tofacitinib | 7 (0.1) |